Create more partnerships between the government and drug companies, with public funding for promising early-stage research.DON'T OVER-REGULATE
Scrutinize all new FDA rules to make sure they don't discourage spending on antibiotics R&D in the future.IMPROVE THE ECONOMICS
When new antibiotics must be used sparingly to fight drug-resistant bugs, extend patent life to compensate companies and encourage them to invest in the future.PROTECT THE PATENTS
Avoid violating the patents on essential drugs such as Cipro. Such violations should only be sanctioned if supplies are inadequate and alternatives don't exist.